The therapy is a highly advanced form of radiation therapy that uses charged particles in the form of a proton that that gets ...

SAN FRANCISCO -- Almost 80% of patients with heavily pretreated advanced/metastatic pancreatic cancer achieved disease ...

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

A man was given two years to live after a colon cancer diagnosis. Now he's healthy thanks to combination of medicine and the ...

UW researchers found potential new treatments for a rare pediatric brain cancer each year that has a median survival time of ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

A team of Australian researchers have developed a new targeted therapeutic approach that could improve treatment for ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic ...

NP-G2-044 (Prilukae), a novel oral fascin inhibitor, has earned orphan drug designation (ODD) from the FDA for the treatment ...

Physical activity, especially walking, significantly reduces fatigue and improves QOL in nonmetastatic colorectal cancer ...